Complexes based on chondroitin for cutaneous absorption

FIELD: pharmacology.

SUBSTANCE: invention is a transdermal delivery composition comprising non-covalent complexes between non-sulphated chondroitin having a molecular weight of 5 to 100 kDa determined by exclusion chromatography and active ingredients selected from diclofenac or its salts and ketorolac or its salts.

EFFECT: invention provides passage through the stratum corneum of the skin, penetration into the epidermis, through the mucous membrane, as well as delayed release of the active components.

4 cl, 11 tbl, 7 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: claimed invention relates to the field of veterinary and is intended for fighting porcine reproductive and respiratory syndrome (PRRS). The method includes the vaccination of pigs with PRRS with the provision of a reduction of hyperthermia duration and protection of lung integrity. The vaccine is obtained by a method, including mixing a live vaccine, prepared for immediate introduction, with an adjuvant-diluent (AD). The said adjuvant-diluent represents an "oil-in water" type emulsion, which contains per 100% of its weight: from 99 to 50 wt % of water and from 1 to 50 wt % of an oil adjuvant. The oil adjuvant contains per 100 % of its weight: from 1 to 95 wt % of at least one mineral oil and from 1 to 80 wt % of at least one SAS. The mineral oil represents oil of a Marcol or Draekol type. SAS represents an ester, obtained by the condensation of a fatty acid with sorbitol or mannitol.

EFFECT: obtaining the preparation for fighting reproductive and respiratory syndrome.

7 cl, 9 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention represents a method for preparing a sterile nanoemulsion of perfluororganic compounds (PFOC) involving: adding a PFOC mixture to an aqueous solution of a stabilising agent; homogenising the PFOC mixture with the aqueous solution of the stabilising agent to produce a PFOC pre-emulsion; mixing the PFOC pre-emulsion with a salt-water solution to produce the PFOC nanoemulsion; keeping the PFOC nanoemulsion at a temperature from 2 to 10°C for at least 18 hours. The method can be also implemented as follows: pre-filling a circulation loop of a PFOC nanoemulsion generating plant with the aqueous solution of the stabilising agent; adding the PFOC mixture to the aqueous solution of the stabilising agent; homogenising the PFOC mixture with the aqueous solution of the stabilising agent to produce the PFOC pre-emulsion; mixing the PFOC pre-emulsion with the salt-water solution to produce the PFOC nanoemulsion.

EFFECT: higher stability of the PFOC emulsion and prolonging the storage life.

30 cl, 7 ex, 5 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and represents emulsion for prevention or treatment of syndrome of inflammatory response and other diseases. Emulsion includes oily component and water component, and oily component contains triglycerides of fish oil and medium-chain triglyceride. Said fish oil triglycerides contain omega-3 fatty acids in quantity at least 60% counted per the total weight of fatty acids of fish oil triglycerides with the total quantity of EPA and DHA constitutes at least 45% counted per the total weight of fatty acids of fish oil triglycerides. Versions of emulsion include vegetable oil in quantity to 10% counted per the total weight of oily component.

EFFECT: emulsion is stable, represents concentrated source of energy and calories, and reduces cytotoxicity of medications.

26 cl, 6 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to chemical-pharmaceutical industry and represents composition of polymeric micelle, suitable for encapsulation and suitable release of medications, which contains block-copolymers, assembled radially and have hydrophobic segment, directed inside, and hydrophilic segment, directed outside, and as block-copolymer it contains block-copolymer, which has affinity to HDL, which contains hydrophobic segment of polymeric chain, formed from hydrophobic amino acid derivative, obtained as a result of introduction of sterol residue into side chain of amino acid, and block-copolymer, which has affinity to lipoprotein, except HDL, which contains hydrophobic segment of polymeric chain, formed from hydrophobic amino acid derivative, obtained as a result of introduction of hydrophobic group, which has linear or branched structure, into side chain of amino acid.

EFFECT: invention ensures stable encapsulation of large-sized medications and their suitable release.

12 cl, 6 ex, 3 tbl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents a method for producing a pharmaceutical emulsion of lactulose involving the preparation stage of sieving a granular material through a sieve with a mesh size of 0.320 mm and 1.0 mm, filtering the lactulose syrup through a sieve with a mesh size of 0.320 mm and the stage of producing the emulsion with dry admixing of the granular material of the emulsion for 5-10 minutes, homogenisation of the lactulose syrup with Simethicon after the preparation stage for 10-15 minutes at a temperature of 25-30°C and at a rotation speed of 400-600 rpm followed by adding the prepared mixture of the granular material and homogenising the mixture for 30-45 minutes; the prepared emulsion is degasified under vacuum for 10 hours at a temperature of 15-25°C until a homogenous mass having a certain ratio of the ingredients is formed, that is followed by sieve filtration at a mesh size of 0.320 mm.

EFFECT: invention provides the higher physiological quality of the ready dosage form in the form of the stable non-toxic emulsion for normalising the action of the bowels, treating and preventing disbioses of various aetiologies, and recovering the normal intestinal flora following antibiotic therapy.

2 cl, 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to production of medications for treating dermatosis. Medication according to invention, made in form of cream, contains mometasone furoate, preservative, hydrophilic no-aqueous solvent, emulsifying agent of 1st kind, emulsifying agent of 2nd kind, emollient, disodium edetate (trilon B), pH-regulating agent, and purified water in quantities, given in invention formula.

EFFECT: invention can be applied for treating inflammatory diseases and itching in case of dermatosis, yielding to glycocorticosteroid therapy.

9 cl, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a balanced fat composition, suitable for probe feeding. The fat composition, suitable for the probe feeding, contains from 8 to 15 wt % of linoleic acid (LA); from 3.0 to 6.0 wt % of a mixture, consisting of ω-3 polyunsaturated fatty acids, alpha-linolenic acid (ALA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), where the quantity of ALA>2.5 wt % and the mixed quantity of DHA and EPA≤2.5 wt %l from 10 to 20 wt % of at least one medium-chain fatty acid (MCFA); and from 35 to 79 wt % of one monounsaturated fatty acid (MUFA). Claimed is a liquid nutritional composition, containing the said fat composition. Claimed is a method of supplying enteral feeding to patients, which includes the introduction of an effective quantity of the said liquid nutritional composition, containing the balanced fat composition by the invention.

EFFECT: invention makes it possible to obtain the balanced nutritional composition for long enteral feeding.

27 cl, 1 dwg, 5 tbl

FIELD: medicine.

SUBSTANCE: invention can be used for the local treatment of trophic ulcers, infected and persistent septic wounds, degrees I-II-IIIA burns, traumatic skin injuries, pyoinflammatory skin diseases, bed sores, etc. The invention refers to a preparation, which contains a streptocide powder 1-2.5 g, Ichthyol ointment 7-10 g and castol oil 87.5-92 ml.

EFFECT: reducing the length of treatment up to 14 days with no side effects.

4 ex

FIELD: chemistry.

SUBSTANCE: method includes milling glauconite with the content of rock from 20 to 95%, selection of a fraction of 1.0-10 mcm, preparation of a 40-80% suspension of glauconite in water. The obtained suspension is processed by ultrasound with a frequency of 15-25 kHz for 2-5 minutes. As a result obtained is a glauconite-based enterosorbent, which represents a 40-80% suspension of the glauconite 1.0-10 mcm fraction in water.

EFFECT: obtaining the glauconite-based enetrosorbent, which has the increased sorption ability in the form of a stable water suspension of glauconite.

2 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a therapeutic agent used for treating or preventing palmar-plantar erythrodysesthesia syndrome (PPES) induced by a multifunction kinase inhibitor (MKI) therapy and containing a therapeutically effective amount of allopurinol or its pharmaceutically acceptable salt.

EFFECT: invention provides extending the range of products for treating or preventing palmar-plantar erythrodysesthesia syndrome (PPES) induced by the multifunction kinase inhibitor (MKI) therapy.

21 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition for control of pain accompanying individual's joint diseases containing hyaluronic acid, which is cross-linked by cycling a double bond in a group of cinnamic acid in partially amidated hyaluronic acid presented by formula (1) to form a cyclobutane cycle, wherein in the above formula, Ar represents a phenyl group, n is equal to an integer 2 or 3; HA represents a carboxy residue of hyaluronic acid, and m represents a relation of amidation of hyaluronic acid to all the carboxyl groups and is equal to 3-50% in relation to all the carboxyl groups, and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition represents a product for injection, wherein the pharmaceutical composition represents the product for injection, wherein the amount of the cross-linked hyaluronic acid makes 1 wt % at the total amount of the product for injection, wherein a single dose of the product for injection makes 2-3 ml, wherein the pharmaceutical composition represents a single-use preparation, which is administered every 13 weeks and more.

EFFECT: invention provides the extremely long analgesic action after the single administration, earlier onset of the analgesic action.

15 cl, 1 dwg, 5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents medication, possessing virucidal activity, for preventive and therapeutic treatment of viral infections, caused by virus of herpesviridae family, characterised by the fact that said medication contains pyroxican in carrier substance.

EFFECT: invention provides extension of arsenal of means, possessing virucidal activity.

7 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a microbiologically stable pharmaceutical composition containing an active agent specified in prostaglandins, and a carrier. The carrier contains an aqueous electrochemically activated saline containing 1 to 500 mg/l of free chlorine and having an oxidation-reduction potential from +150 to +1350 mV. The active agent is present in a phase separated from the electrochemically activated saline; the electrochemically activated saline is a hypochlorite solution.

EFFECT: invention refers to using the pharmaceutical composition for treating and/or preventing dry eye syndrome and for cleansing contact lenses.

14 cl, 5 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relate to field of pharmaceutics and deal with pharmaceutically stable compositions, which contain human antibody, specifically bound with human interleukine 6 (hIL-6R) receptor, where said human antibody is contained in concentration from 5 to 200 mg/ml and includes variable region of light chain with amino acid succession SEQ ID NO:26, histidine, arginine, sucrose, polysorbate.

EFFECT: group of inventions ensure considerable degree of antibody stability after storing for several months.

22 cl, 8 ex, 28 tbl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an injectable therapeutic anti-cancer formulation administered into cancer cells directly. The formulation contains 5-25% (wt/vol) of hydroxychloroquine or hydroxychloroquine sulphate, Lidocaine concentrated 1-2% (wt/vol), Riboflavin concentrated 0.1-0.5% (wt/vol) and physiologic saline.

EFFECT: invention provides the formulation which exhibits cytotoxic effect on the cancer cells without involving normal cells, and which is administered into the cancer cells directly.

2 cl, 3 tbl, 4 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition in the form of a liquid solution for nasal administration of spray containing naltrexone in an amount of 0.005-0.02 wt/vl %.

EFFECT: invention provides eliminating the undesired side effects with preserving naltrexone activity.

6 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine. Described is medical form for transmucousal per oral introduction of, at least, one active substance of antispasmodic and/or analgesic action, which contains said active substance in form of base and/or in form of salt, water-alcohol solution, with alcoholic content, at least, 35° of alcohol by weight, with said active substance being present in water-alcohol solution in condition of stable and complete dissolution. Invention also relates to method of said medical form preparation and its application for treating spastic attacks.

EFFECT: medical form makes it possible to realise instantaneous transmucousal per oral introduction.

10 cl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely represents a method for the therapy of respiratory symptom. The method involves administering a liquid composition containing a gel former and/or a mucoactive polymer, a non-menthol cooling substance; and contacting the oral mucosa with the liquid composition. The invention also describes liquid compositions applicable in the method for the therapy of a respiratory disease.

EFFECT: implementing the method provides improving the cooling properties of the cooling agent N-(4-cyanomethylphenyl)-n-menthane carboxamide in the liquid composition by combining the non-menthol cooling substance with the gel former.

14 cl, 2 tbl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to the field of pharmaceutics and deals with a pharmaceutical composition, which contains feline erythropoietin as an active ingredient, to which two or more polyethyleneglycol molecules with a non-branched chain are attached, with a water-soluble long-chain molecule having the molecular weight, constituting not less than 30 kDa and producing the haemopoietic effect. A haemopoietic medication and a medication for the treatment of anaemia are based on the said composition.

EFFECT: group of inventions provides the haemopoietic effect, which lasts for not less than seven days, when introduced to humans and/or animals.

8 cl, 4 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a composition for preventing and treating allergic conjunctivitis and keratoconjunctivitis, containing cromoglicic acid, boric acid and water-soluble polymers specified in a group of: carbomer, hypromellose, macrogol and polyvinylpyrrolidone with the components of the composition taken in specific relations, g in 1 ml of the mixture.

EFFECT: invention provides the better reduction of the inflammatory process and symptoms of the disease; there are also ensured ease of use with a smaller frequency of administration, prolonged action and no side effects.

5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutics. Gel form of azelaic acid is described. Gel form includes micronized azelaic acid and additional substances: benzoic acid, disodium edetate, carbomer Carbopol 980, propylene glycol, sodium hydroxide, glycoceramides purified, isopropylmiristate, polysorbate 20, purified water.

EFFECT: invention is provided by obtaining stable medication in form of gel, which does not produce local irritating action in case of long-term on-skin applications.

11 cl, 15 dwg, 5 tbl

Up!